Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BMRANASDAQ:CELZNASDAQ:NEUPNASDAQ:NTBL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBMRABiomerica$3.12-1.9%$3.95$1.93▼$10.16$7.94M0.37275,827 shs6,267 shsCELZCreative Medical Technology$1.97-3.9%$2.07$1.69▼$6.90$5.09M250,122 shs17,394 shsNEUPNeuphoria Therapeutics Inc. - Common Stock$6.52-3.3%$5.27$2.12▼$12.72$12.26M0.26350,730 shs17,496 shsNTBLNotable Labs$0.25$0.33$0.22▼$4.24$2.24M0.981.01 million shs2.11 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBMRABiomerica+2.25%-12.64%-18.04%-46.79%-36.50%CELZCreative Medical Technology+1.49%+2.50%+4.06%-59.00%-52.44%NEUPNeuphoria Therapeutics Inc. - Common Stock-0.59%+24.81%+33.73%+31.13%+673,999,900.00%NTBLNotable Labs0.00%0.00%0.00%0.00%-69.01%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBMRABiomerica0.6369 of 5 stars0.05.00.00.01.90.80.0CELZCreative Medical Technology1.5005 of 5 stars0.05.00.00.03.30.01.3NEUPNeuphoria Therapeutics Inc. - Common Stock1.5483 of 5 stars3.50.00.00.02.20.00.6NTBLNotable LabsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBMRABiomerica 0.00N/AN/AN/ACELZCreative Medical Technology 0.00N/AN/AN/ANEUPNeuphoria Therapeutics Inc. - Common Stock 3.00Buy$21.00222.09% UpsideNTBLNotable Labs 2.00HoldN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBMRABiomerica$5.68M1.40N/AN/A$0.39 per share8.00CELZCreative Medical Technology$14K363.89N/AN/A$7.48 per share0.26NEUPNeuphoria Therapeutics Inc. - Common Stock$15.66M0.78N/AN/A$7.82 per share0.83NTBLNotable Labs$313K7.14N/AN/A$6.81 per share0.04Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBMRABiomerica-$5.98M-$2.32N/A∞N/A-100.52%-90.19%-64.54%N/ACELZCreative Medical Technology-$5.29M-$3.81N/AN/AN/AN/A-63.05%-60.42%8/8/2025 (Estimated)NEUPNeuphoria Therapeutics Inc. - Common Stock-$15.49MN/A0.00N/AN/AN/AN/AN/AN/ANTBLNotable Labs-$11.26MN/A0.00∞N/AN/A-80.81%-62.86%N/ALatest NTBL, BMRA, CELZ, and NEUP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2025Q3 2025NEUPNeuphoria Therapeutics Inc. - Common Stock-$0.47$6.55+$7.02$6.55N/A$15.00 million5/9/2025Q1 2025CELZCreative Medical Technology-$0.52-$0.83-$0.31-$0.83N/A$0.00 million4/14/2025Q3 2025BMRABiomericaN/A-$0.48N/A-$0.06N/A$1.12 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBMRABiomericaN/AN/AN/AN/AN/ACELZCreative Medical TechnologyN/AN/AN/AN/AN/ANEUPNeuphoria Therapeutics Inc. - Common StockN/AN/AN/AN/AN/ANTBLNotable LabsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBMRABiomericaN/A3.172.22CELZCreative Medical TechnologyN/A19.1319.12NEUPNeuphoria Therapeutics Inc. - Common StockN/A2.063.30NTBLNotable Labs0.032.772.77Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBMRABiomerica22.28%CELZCreative Medical Technology1.42%NEUPNeuphoria Therapeutics Inc. - Common Stock15.90%NTBLNotable Labs70.48%Insider OwnershipCompanyInsider OwnershipBMRABiomerica15.00%CELZCreative Medical Technology1.80%NEUPNeuphoria Therapeutics Inc. - Common Stock0.69%NTBLNotable Labs1.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBMRABiomerica602.55 million15.59 millionOptionableCELZCreative Medical Technology52.59 million1.70 millionNot OptionableNEUPNeuphoria Therapeutics Inc. - Common StockN/A1.88 million1.75 millionN/ANTBLNotable Labs409.02 million9.54 millionNo DataNTBL, BMRA, CELZ, and NEUP HeadlinesRecent News About These CompaniesNotable Labs, Ltd. (NTBLQ)February 13, 2025 | finance.yahoo.comWhat Factors Have Led to Notable Labs Ltd (NTBL) Stock Trading -93.03% Below Its 52-Week High?October 22, 2024 | bovnews.comNotable Labs Ltd (NTBL) Stock: Greater Than Its Current Valuation?October 18, 2024 | bovnews.comNotable Labs files for bankruptcy, ending ambitions for Boehringer cancer drugOctober 16, 2024 | fiercebiotech.comNotable Labs Pauses Implementation of Cancer Drug Volasertib Study, Announces LayoffsSeptember 20, 2024 | marketwatch.comNotable Labs (NTBL) was downgraded to a Hold Rating at JMP SecuritiesSeptember 20, 2024 | markets.businessinsider.comNotable Labs to Present Data on September 4th at SOHO 2024August 29, 2024 | globenewswire.comNotable Labs Announces CEO TransitionAugust 27, 2024 | finance.yahoo.comNTBL Stock Earnings: Notable Labs Misses EPS for Q2 2024August 16, 2024 | investorplace.comLA’s best burrito is a lab-engineered marvelAugust 15, 2024 | msn.comNotable Labs: Q2 Earnings SnapshotAugust 15, 2024 | sfgate.comNotable Labs, Ltd. (NTBL)July 26, 2024 | finance.yahoo.comIt’s Better to Hope for Prosperity than Become Adversary: Notable Labs Ltd (NTBL) StockJuly 25, 2024 | bovnews.comNotable Labs Cleared by FDA to Begin Phase II Trial of Volasertib in AMLJuly 24, 2024 | precisionmedicineonline.comNotable Labs Receives FDA Clearance to Proceed Further with Volasertib Phase 2 StudyJuly 24, 2024 | globenewswire.comNPC Labs raises $18M to bring mainstream games to Web3July 22, 2024 | venturebeat.comBears are Losing Control Over Notable Labs (NTBL), Here's Why It's a 'Buy' NowMay 24, 2024 | zacks.comOppenheimer raised the price target for the Notable Labs Ltd (NASDAQ:NTBL) stock to “”a Perform””May 24, 2024 | bovnews.comNTBL Stock Earnings: Notable Labs Misses EPS for Q1 2024May 16, 2024 | investorplace.comBuy Rating Affirmed for Notable Labs Amid Promising Drug Program and Robust PPMP PlatformMay 16, 2024 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNTBL, BMRA, CELZ, and NEUP Company DescriptionsBiomerica NASDAQ:BMRA$3.12 -0.06 (-1.89%) Closing price 03:55 PM EasternExtended Trading$3.16 +0.04 (+1.44%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops products to indicate if a person has been infected by COVID-19. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.Creative Medical Technology NASDAQ:CELZ$1.97 -0.08 (-3.90%) Closing price 03:59 PM EasternExtended Trading$1.97 0.00 (0.00%) As of 04:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.Neuphoria Therapeutics Inc. - Common Stock NASDAQ:NEUP$6.52 -0.22 (-3.26%) As of 03:51 PM EasternNeuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.Notable Labs NASDAQ:NTBLNotable Labs, Ltd., a clinical-stage platform therapeutics company, develops predictive precision medicines for patients with cancer. The company, through its proprietary Predictive Precision Medicines Platform (PPMP), bio-simulates a cancer treatment and predicts, whether or not the patient will clinically respond to their actual treatment. Its PPMP is designed to identify and select clinically responsive patients prior to their treatment and enables fast-track therapeutic development in this patient population. The company's pipeline includes Volasertib, a potent Polo-like kinase 1 (PLK-1) inhibitor to induce cell cycle arrest and apoptosis in various cancer cells; and Fosciclopirox, a pro-drug of ciclopirox for acute myeloid leukemia. Notable Labs, Ltd. was incorporated in 2014 and is headquartered in Foster City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock GameStop Buys Bitcoin: Smart Strategy or Big Mistake? Qualcomm Stock Turns South: 3 Entry Signals to Watch For D-Wave Quantum Stock: Are Advantage2 Gains Here to Stay? Meta's Institutional & Insider Data Fuels Bulls Despite Disparity Is Michael Burry Right Betting Against the Market Again? Microsoft's Outlook Brightens as Analysts Boost Bullish Ratings ThredUp Stock Reverses on AI Buzz, Eyes Double-Digit Gains Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
